Physician profile
Laura Robert
NPI 1235111899
$10,347.98
in general payments reported to CMS, 2019-2025
46 companies · $1,716 in 2025
The $1,716 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $1,075 · 2021: $1,850 · 2022: $1,395 · 2023: $1,369 · 2024: $1,589 · 2025: $1,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,628 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,628.49 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,478.31 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,059.51 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $931.19 | 2019-2025 | |
| Abbvie INC. | $679.05 | 2021-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $604.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $596.53 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $586.84 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $533.92 | 2019-2025 | Jardiance |
| Amgen INC. | $494.74 | 2019-2025 | Evenity, Otezla, Repatha |
| Amarin Pharma, INC. | $280.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $265.28 | 2019-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $262.94 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $234.58 | 2019-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $212.49 | 2019-2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $177.95 | 2021-2025 | Nexletol |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Robert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.